Embryonic stem cell-derived extracellular vesicles rejuvenate senescent cells and antagonize aging in mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37449253.
- Also identified by DOI 10.1016/j.bioactmat.2023.06.011 and PMC identifier 10336196.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aging is a degenerative process that leads to tissue dysfunction and death. Embryonic stem cells (ESCs) have great therapeutic potential for age-related diseases due to their capacity for self-renewal and plasticity. However, the use of ESCs in clinical treatment is limited by immune rejection, tumourigenicity and ethical issues. ESC-derived extracellular vesicles (EVs) may provide therapeutic effects that are comparable to those of ESCs while avoiding unwanted effects. Here, we fully evaluate the role of ESC-EVs in rejuvenation <i>in vitro</i> and <i>in vivo</i>. Using RNA sequencing (RNA-Seq) and microRNA sequencing (miRNA-Seq) screening, we found that miR-15b-5p and miR-290a-5p were highly enriched in ESC-EVs, and induced rejuvenation by silencing the <i>Ccn2</i>-mediated AKT/mTOR pathway. These results demonstrate that miR-15b-5p and miR-290a-5p function as potent activators of rejuvenation mediated by ESC-EVs. The rejuvenating effect of ESC-EVs was further investigated <i>in vivo</i> by injection into aged mice. The results showed that ESC-EVs successfully ameliorated the pathological age-related phenotypes and rescued the transcriptome profile of aged mice. Our findings demonstrate that ESC-EVs treatment can rejuvenate senescence both <i>in vitro</i> and <i>in vivo</i> and suggest the therapeutic potential of ESC-EVs as a novel cell-free alternative to ESCs for age-related diseases.